Parexel rebounds from a shaky fall as sales jump 15%

Parexel CEO Josef von Rickenbach

After a hiccup in new business alarmed investors and overshadowed steady gains, Parexel International ($PRXL) righted the ship in its second fiscal quarter, boosting its new contracts and growing revenue by about 15%.

Parexel's net new business wins totaled $654.7 million, a 66% sequential jump over the $394 million that startled investors last quarter. On the revenue side, the CRO hauled in $487.1 million, besting $422.1 million from the prior year period, and net income jumped 33% to $28.3 million on the quarter.

As usual, Parexel's clinical research services business led the way with $363.9 million in revenue, a 14% increase, while its consulting segment grew 12% to $55.5 million and Perceptive Informatics, its IT unit, leapt 30% to $67.7 million. That puts Parexel on track to meet its roughly $1.9 billion revenue expectation for the fiscal year, CEO Josef von Rickenbach said, thanks in part to the company's return to a healthy book-to-bill ratio of 1.34.

"I believe the market for our products and services continues to be strong," von Rickenbach said in a statement. "We remain focused on successfully competing in the marketplace, executing projects with high quality and driving efficiency initiatives throughout our businesses."

Parexel's shares climbed as high as $50 after its quarterly results came out, a roughly 28% jump from their December nadir when investors seemed to lose faith in the global giant's ability to keep up with rivals like Quintiles ($Q) and Covance ($CVD).

However, while Parexel's positive second quarter suggests its previous slump in contract signing was just a blip, the CRO is still likely to see that swoon's effects on revenue at some point down the line.

- read the results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.